

**MDS case study:  
80-year-old female with macrocytic anemia**

---

# MDS case study

**Consultation:** a 80-year-old woman was referred to our institution in 2006 because of a persistent macrocytic anemia. She presented with tiredness and dizziness.

## **Medical history:**

No allergies. Non-smoker.

- Mild vitamin B12 deficiency and macrocytic anemia diagnosed in 2005.

Despite of the correct treatment with intramuscular vitamin B12, the anemia persisted.

- Chronic atrophic gastritis.
- Hypertension.

**Physical examination:** skin pallor with no other significant abnormalities.

# MDS case study

## Blood tests (I):


- RBC  $91 \times 10^9/L$ , **Hb 7.4 g/dL**, Htc 22.9%, **MCV 119.9 fL**, MHC 38.7pg, WBC  $5.14 \times 10^9/L$ , platelets  $306 \times 10^9/L$ . Reticulocytes: 2.59 %, total  $49.5 \times 10^9/L$ .
- Glucose 120 mg/dl, Creatinine 0.99 mg/dl, LDH 329 UI/L, Bilirubin 0.53 mg/dl, AST 12 UI/L, ALT 9 UI/L, GGT 60 UI/L, AF 40 UI/L, Total proteins 6.9 g/dL, Albumin 4.4 g/L, EPO 678 mU/mL, Vitamin B12 464 pg/mL, Folic acid 10.9 ng/mL, Ferritin 126 ng/mL.
- HBV, HCV, HIV negatives.
- Prothrombin rate 71%, aPTT 27 seg.


# MDS case study


## Blood tests (II):

- Peripheral blood smear:

- WBC differential count: 64N, 4Eo, 0B, 28L, 4M.
- Anisopoikilocytosis, macrocytosis, polycromasia, basophilic stippling. Some schistocytes, elliptocytes and dacryocytes.
- Anisocytosis of platelets.
- Doble population of neutrophils: coexistence of normal and marked hypogranulated elements.







# MDS case study

## **Bone marrow aspirate:**

Hypercellular.

Megakaryopoiesis: abundant. **58%** of dysmorphic elements: small megakaryocytes **with hypo- or monolobated nucleus**.

Erythropoiesis: **15%**. Asynchronic maturation, nuclear budding, altered mitosis, irregular distribution of hemoglobin and presence of Höwell-Jolly bodies.

Granulopoiesis: 61%. Hypogranulated neutrophils with Döhle bodies.

**6% blasts** (3% type I and 3% type II).


Mononuclear phagocytic system: 3%.

Lymphocytes: 19%.


Plasma cells: 2%

Normal macrophagic iron store. Sideroblasts type I and II: 48%. No ring sideroblasts.

































# MDS case study

## Bone marrow karyotype:

46,XX,del(5)(q13q33)[14]/46,XX[6]





# MDS case study

## Diagnosis:

Myelodysplastic syndrome with isolated del (5q)

vs

Refractory anemia with excess blasts type I (6% blasts in BM)

# Classification of MDS: WHO 2008

Subtipo	Cytopenia	Blasts PB (%)	Blasts BM %	% ring SB in BM	Dysplasia
<b>RCUD</b>	1 or 2 cytopenias	<1	<5	<15	1 cell line
<b>RARS</b>	Anaemia	0	<5	≥15	Erythroid
<b>RCMD</b>	Cytopenia/s	<1	<5 No Auer R.	<15 o ≥15	≥2 líneas
<b>RAEB-1</b>	Cytopenia/s	<5	5-9 No Auer R.	Indifferent	Indifferent
<b>RAEB-2</b>	Cytopenia/s	5-19 (+/- Auer R.)	10-19 +/- Auer R.	Indifferent	Indifferent
<b>MDS associated with isolated del(5q)</b>	Anaemia	<1	<5	Indifferent	Indifferent
<b>Unclassified MDS</b>	Cytopenias	=1	<5		<10% in ≥ 1 cell lines and CG abnormality
<b>ICUS (provisional)</b>	Cytopenias > 6 months	0	<5	0	NO displasia NO CG abnormality

# Classification of MDS: WHO 2008

Subtipo	Cytopenia	Blasts PB (%)	Blasts BM %	% ring SB in BM	Dysplasia
<b>RCUD</b>	1 or 2 cytopenias	<1	<5	<15	1 cell line
<b>RARS</b>	Anaemia	0	<5	≥15	Erythroid
<b>RCMD</b>	Cytopenia/s	<1	<5 No Auer R.	<15 o ≥15	≥2 líneas
<b>RAEB-1</b>	Cytopenia/s	<5	5-9 No Auer R.	Indifferent	Indifferent
<b>RAEB-2</b>	Cytopenia/s	5-19 (+/- Auer R.)	10-19 +/- Auer R.	Indifferent	Indifferent
<b>MDS associated with isolated del(5q)</b>	Anaemia	<1	<5	Indifferent	Indifferent
<b>Unclassified MDS</b>	Cytopenias	=1	<5		<10% in ≥ 1 cell lines and CG abnormality
<b>ICUS (provisional)</b>	Cytopenias > 6 months	0	<5	0	NO displasia NO CG abnormality

# MDS case study

## Diagnosis:

Myelodysplastic syndrome with isolated del (5q)

vs

**Refractory anemia with excess blasts type I (6% blasts in BM)**

## Prognosis:

IPSS: intermediate risk-I (score 0.5 for blasts count).

WPSS: high risk (score 3 for WHO subtype and transfusion requirement).


# MDS case study

## **Outcome:**

- Initially, she was treated only with supportive therapy.
- On April 2008 the patient started treatment with lenalidomide with no transfusion requirement since then.
- Bone marrow study in July 2008:
  - reduction of dismorphic features (<10% monolobated megakaryocytes).
  - karyotype: 46,XX[20].
  - FISH: 5q31 in 3.5% nuclei.
- On March 2009, the patient presented exacerbation of the anemia (Hb 7.7 g/dL). Bone marrow study showed:
  - Karyotype: 46,XX,del(5)(q13q33)[9]/46,XX[11].
  - FISH: 5q31 in 32% nuclei.

# MDS case study

## Hemoglobin level evolution



# MDS case study

## **MDS associated with isolated del(5q)**

MDS characterized by:

- Anemia with or without cytopenias and/or thrombocytosis
- Blasts in bone marrow <5%
- Blasts in PB<1%
- No Auer rods
- Isolated del(5q)

## **5q- Syndrome**

- Clinical picture described by Van den Berghe in 1974
- Higher incidence in older women
- Macrocytic anemia
- Normal or elevated platelet count
- Erythroid hypoplasia
- Blasts in bone marrow <5%
- Blasts in PB<1%
- Isolated del(5q)

# MDS case study


---

- The commonly deleted region in patients with the 5q-syndrome was mapped to a region of 1.5 MB between 5q31 and 5q33
- Sequencing of genes located in these regions did not reveal mutations, suggesting that haploinsufficiency of one or more genes contributes to the development of the disease



## GENES IMPLICATED IN THE PATHOGENESIS OF MDS

Genes	Chr. Localisation	% (MDS)	
TET2	4q24	25	} Its presence indicates clonality
RPS14	5q32	15	
CTNNA1	5q31	15	
Mir145/146 <sup>a</sup>	5q33	15	
AXL1	20q11.21	10	
N-RAS	1p13.2	10	
P53	17p13.1	5-10	
RUNX1/AML1	21q22.3	5-10	
NPM1	5q35	5	
JAK2	9p24	5	
FLT3	13q12	2-5	
C/EBPalpha	19p13.1	1-4	
EVI-1	3q26	2	
CBL	11q23.3	1-2	
EZH2	20	6	



**Figure 4. Ideograms and Commonly Deleted Regions Involving Del(5q).**

In typical 5q minus syndrome, the commonly deleted region (CDR) has been mapped to 5q33.1 (at right), which contains *SPARC*, the gene encoding osteonectin (secreted protein, acidic, cysteine-rich), and *RPS14*, the gene encoding ribosomal protein S14. In the *del(5q)*-associated myelodysplastic syndrome–acute myeloid leukemia, the commonly deleted region has been mapped to 5q31.2 (at left), which contains genes encoding catenin alpha 1 (*CTNNA1*), early growth response 1 (*EGR1*), and cell division cycle 25 homologue C (*CDC25C*).